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OBJECTIVES:Overall expenditure for the treatment of ACS imposes a heavy burden
on global health care systems. As new treatments and procedures have become
available in the past decade, the cost to healthcare systems has increased, yet
mortality rates have remained relatively high. A recent research effort was under-
taken to benchmark expenditures and outcomes in patients with ACS. The aim of
this study was to understand the efficiency of resource use, in relation to mortality
for patients with ACS in the UK. METHODS: A systematic literature search of 11
databases and secondary desk research were performed to identify ACS related
expenditure and outcomes. Data were retrieved for UK patients with MI (STEMI,
NSTEMI) and unstable angina. The reported cost data were extracted for hospital-
izations, procedures, pharmaceutical treatment, and monitoring; mean annual ex-
penditure per patient was estimated based on of these cost components. Outcomes
focused on ACS mortality rate over the entire UK population. RESULTS: In the UK,
the overall annual mortality rate for ACS was found to be 0.0473%. Total annual
expenditure for all patients with ACS was £392,245,277 (£3,733 per patient). Results
showed hospitalizations to be the main cost driver, accounting for 65.7% of the
total annual cost. Procedure costs represented 24.5% of the total cost, whereas
pharmaceutical treatment and monitoring costs accounted for 5.3% and 4.5%,
respectively. CONCLUSIONS: The findings of this systematic review demonstrate
that hospitalization cost accounts for almost two thirds of the total direct cost
associated with ACS in the UK. More research and cross-country comparison are
needed to determine treatment strategies which provide greater efficiency in re-
source use for the management of ACS.
PCV60
COST-EFFECTIVENESS OF DABIGATRAN FOR THE PREVENTION OF STROKE IN
PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN AUSTRALIA
Tilden D1, Germanos P2, Gordon J2, Tocchini L1, Monz B3
1THEMA Consulting Pty Ltd, Pyrmont, NSW, Australia, 2Boehringer Ingelheim Pty Limited, North
Ryde, NSW, Australia, 3Boehringer Ingelheim GmbH, Ingelheim am Rhein, Germany
OBJECTIVES: The objective of this cost-utility analysis was to compare the costs
and effectiveness of dabigatran (DAB) with adjusted dose warfarin (WAR), aspirin
(ASP) or no treatment (UNT) in patients with Non-Valvular Atrial Fibrillation
(NVAF), from the perspective of the third party payer in the Australian public
healthcare system. METHODS: A Markov cohort model was constructed based on
the pivotal RE-LY clinical trial and indirect comparisons with aspirin and no treat-
ment. The model calculated the incremental cost per QALY of different dabigatran
doses (150 mg BID or 110 mg BID) relative to adjusted-dose warfarin, aspirin or no
treatment. The model estimated the number of ischaemic strokes (IS), haemor-
rhagic strokes (HS), systemic embolic events (SEE), intracranial haemorrhages
(ICH), transient ischaemic attacks (TIA), extra-cranial haemorrhages (ECH), minor
bleeds (MB) and myocardial infarctions (AMI) associated with the respective treat-
ments. The key consequences of the clinical events were costs, disability and/or
reduction in quality of life, and death. The costs, morbidity and mortality of IS and
HS in Australia were estimated from a patient audit of 3,307 strokes in Australia.
RESULTS: The dabigatran treatment groups were associated with greater life years
and QALYs compared with all the other treatment groups. These gains were pri-
marily driven by a lower incidence of IS, SEE, TIA, ICH and HS in most comparisons.
Incremental cost per QALY ratios were calculated by comparing the expected util-
isation of the dabigatran doses (50% of patients using each dose) with current
utilisation of adjusted-dose warfarin (40%), aspirin (40%) and no treatment (20%).
The incremental cost per QALY of dabigatran was $10,028. Sensitivity and sub-
group analyses consistently demonstrated the cost-effectiveness of dabigatran.
CONCLUSIONS: Treating patients with dabigatran represents a cost-effective
treatment for preventing strokes in patients with NVAF in Australia.
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OBJECTIVES:To estimate the costs for the first clinically diagnosed stroke, in Spain.
METHODS: Observational prospective study conducted in 16 Spanish centers
(CONOCES study; Costes Socioeconómicos del Ictus en España). Patients will be
followed during a 1 year period; 3 visits will be performed (inpatient hospitalization
due to stroke, 3 and 12 months after stroke). Patient inclusion was controlled by the
presence of Atrial Fibrilation (AF). Currently, hospitalization data from the first visit
has been collected including patients’ demographics, stroke severity, patient sta-
tus and QoL at discharge, and direct resource consumption: length of stay, imaging
and laboratory tests, specific therapeutic interventions (thrombolysis, decompres-
sive craniectomy, angioplasty. . .), supporting therapies, and medication. Unitary
costs were obtained from national healthcare databases and the Spanish Catalogue
of Medicinal Products (€, year 2011 values). RESULTS: A total of 322 patients were
recruited from November 2010 to May 2011. Preliminary results from the first visit
showed the following characteristics: 50.3% had AF, mean age of 71.9511.57,
44.6% female, 28.6% with intravenous thrombolysis, NIH 6.728.11, modified
Rankin Score 3.041.85, Barthel index 56.7138.68. Mortality rate during stay was
6.2%. Only 257 patients were evaluable for economic purposes. Mean length of
hospital stay was 9.65 days (95%CI, 8.71-10.60). Mean inpatient cost per patient was
€6428 (95% confidence interval [CI], €5912-€6943). The most relevant categories of
costs were inpatient hospitalization (€3960, 95%CI, €3574-€4347, 61.6% of direct
hospitalization costs), specific therapeutic interventions (€984, 95%CI, €783-€1185,
15.3%), imaging tests (€951, 95%CI, €878-€1024, 14.8%), medication (€302, 95%CI,
€209-€394, 4.7%), laboratory tests (€145, 95%CI, €126-€164, 2.3%), and supporting
therapies (€86, 95%CI, €45-€127, 1.3%).CONCLUSIONS:The inpatient economic bur-
den of stroke in Spain is substantial because of long hospital stays and other health
resource utilization. Results from this study show higher costs than previously
published data.
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OBJECTIVES: To determine the effect of the use of tobacco in the consumption of
health care resources and their associated costs in patients who have suffered
some kind of cardiovascular event (CVE) in a populational scope. METHODS: Mul-
ticentric observational study undertaken through the retrospective review of the
medical records of patients at six primary health-care centres and two hospitals.
Inclusion criteria: subjects  30 years, who requested health care after suffering a
CVE between 2003 and 2007. Follow-up: 36 months. Groups: smokers, ex-smokers
and non-smokers. Variables: Main measures: sociodemographics, comorbidities,
resources used and total costs (health related, [primary care settings and hospitals]
and productivity losses [absenteeism days]). Statistical analysis: logistic regression
model and ANCOVA (procedure: marginal means; adjustment: Bonferroni); p
0.05. RESULTS: A total of 2540 patients fulfilled the inclusion criteria (smokers:
8.4%, ex-smokers: 52.9%, non-smokers: 38.7%). Mean age: 68.1 years old; men:
60.7%. Smoking addiction was related with COPD (OR2.4; 95%CI: 1.7-3.5) and de-
pressive syndrome (OR1.5; 95%CI: 1.1-2.2). Smokers patients, compared to ex-
smokers and non-smokers, needed more hospitalization days (2.4 vs. 1.7 and 1.1;
p0.001), more specialized health care visits (2.2 vs. 1.5 and 1.3; p0.001) and
incurred more absenteeism days (36.7 vs. 30.7 and 10.5; p0.001) respectively. Total
costs: €16.8 millions (health related: 78.4%; productivity losses related: 21.6%; mean
annual cost/patient: €6,309.8). Annual costs were higher among smokers in com-
parison with ex-smokers and non-smokers (€ 7,980.70 versus € 7,322.10 and €
5,618.90; p  0.001); in terms of both health-care costs (€ 6,272.90 versus € 5,672.50
and € 4,822.90; p  0.001) and losses of productivity at work (€ 1,707.70 versus €
1,649.60 and € 796.00; p  0.001), respectively. CONCLUSIONS: In routine clinical
practice, smokers patients compared to ex-smokers and non-smokers, show a
higher cost from a societal perspective, both in health care related costs and in
labour productivity losses.
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OBJECTIVES: To quantify direct health care costs of oral vitamin K antagonist
anticoagulant treatment in patients diagnosed with non valvular atrial fibrillation
(NVAF). We examine whether a correlation exists between poor INR control and
direct health care costs. METHODS: We designed an observational study. We re-
vised the clinical histories of patients diagnosed with NVAF and treated with OATs
at the Fundación Jiménez Díaz (FJD) between 01/10/2009 and 30/09/2010 (N1,257).
We collected INR value, number of visits due to INR control, type of anticoagulant
(warfarin or acenocoumarol), hospital admissions due to complications and other
current medication. The cost of all drugs was assumed to be the official price.
Expenditure in INR control was calculated using the costs of all health care re-
sources involved in the procedure. We used DRGs for the cost of each hospitalisa-
tion. The cost of a hospital visit was calculated using four scenarios, using actual
invoices or using analytical accountancy methods. All costs are expressed in 2010
euros. RESULTS: The monthly average number of visits per patient was 1.17. Direct
health care costs are in the range of 423,695€ and 1,436,038€. The average cost per
patient varies between 392€ and 1,341€. The average cost of those patients with an
INR within therapeutic range in 25% of the visits was 441.70€-1,592€. When INR was
within therapeutic range in 25%-50% of the visits the average cost was 512.37€-
1,703.91€. INR within therapeutic range in 50%-75% of the visits represented an
average cost of 400.80€-1,375.74€. When INR was within therapeutic range in over
75% of the visits the average cost decreased to 305.23€-1,049.84€. CONCLUSIONS:
The main part of direct health care costs of treating NVAF patients with OAT are
due to hospital control in a specialised area and the high frequency of the visits.
There is an inverse relationship between good INR control and direct health care
costs.
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